China SXT Pharmaceuticals (China SXT Pharmaceuticals) Buyback Yield % : 0.00 (As of Jun. 06, 2024)

View and export this data going back to 2019. Start your Free Trial

What is China SXT Pharmaceuticals Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

China SXT Pharmaceuticals's current buyback yield was 0.00%.

China SXT Pharmaceuticals Buyback Yield % Historical Data

The historical data trend for China SXT Pharmaceuticals's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China SXT Pharmaceuticals Buyback Yield % Chart

China SXT Pharmaceuticals Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Buyback Yield %

Get a 7-Day Free Trial

-4.19

-27.38

-67.69

China SXT Pharmaceuticals Semi-Annual Data
	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Buyback Yield %	Get a 7-Day Free Trial									-	-	-	-	-

Competitive Comparison of China SXT Pharmaceuticals's Buyback Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, China SXT Pharmaceuticals's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China SXT Pharmaceuticals's Buyback Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China SXT Pharmaceuticals's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where China SXT Pharmaceuticals's Buyback Yield % falls into.

China SXT Pharmaceuticals Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

China SXT Pharmaceuticals's Buyback Yield for the fiscal year that ended in Mar. 2023 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	2.195)	/	3.2426824
	=	-67.69%

China SXT Pharmaceuticals's annualized Buyback Yield for the quarter that ended in Sep. 2023 is calculated as

Buyback Yield	=	Net Issuance of Stock		(Annualized)			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	*	Annualized Factor	/	Market Cap
	=	- (0	+	0)	*	2	/	2.23813875
	=	0.00%

In calculating the annualized semi-annual data, the Repurchase of Stock and Issuance of Stock data used here is two times the semi-annual (Sep. 2023) data.

China SXT Pharmaceuticals Buyback Yield % Related Terms

Thank you for viewing the detailed overview of China SXT Pharmaceuticals's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

China SXT Pharmaceuticals (China SXT Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China SXT Pharmaceuticals Inc (NAS:SXTC) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

2RY0:Germany

Address

No. 178 Taidong Road North, Jiangsu, Taizhou, CHN, 225300

Website

http://www.sxtchina.com

China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, Advanced TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates a majority of its revenue from the People's Republic of China.